XRTXF - XORTX Therapeutics Inc.

Other OTC - Other OTC Delayed Price. Currency in USD

XORTX Therapeutics Inc.

421 7th Avenue SW
Suite 4000
Calgary, AB T2P 4K9
Canada
403 455 7727
http://www.xortx.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Dr. Allen W. DavidoffFounder, CEO, Pres & DirectorN/AN/AN/A
Mr. James Neville FairbairnChief Financial OfficerN/AN/A1963
Dr. Alan F. MooreExec. Consultant of Clinical & Regulatory AffairsN/AN/A1948
Charlotte MayCorp. Sec.N/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

XORTX Therapeutics Inc., a bio-pharmaceutical company, focuses on the development and commercialization of therapies to treat progressive kidney diseases worldwide. It has two lead programs, including treatments for progressive kidney disease due to diabetes, diabetic nephropathy and polycystic kidney disease. The company focuses on developing therapies for health consequences that includes pre-diabetes, diabetes, and cardiovascular disease. In addition, it develops uric acid lowering agents to treat diabetic nephropathy, hypertension, insulin resistance, metabolic syndrome, and diabetes; and xanthine oxidase inhibitors. The company has strategic alliance with Teijin Pharma Limited to develop TMX-049, a xanthine oxidoreductase. XORTX Therapeutics Inc. is headquartered in Calgary, Canada.

Corporate Governance

XORTX Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.